EyeWorld is the official news magazine of the American Society of Cataract & Refractive Surgery.
Issue link: https://digital.eyeworld.org/i/78716
March 2012 EW CORNEA 71 SAR 1118 (SARcode Bioscience, Brisbane, Calif.): A first-in-class small molecule integrin antagonist, SAR 1118 works to in- hibit T-cell activation, adhesion, mi- gration, proliferation, and cytokine release by blocking two key surface proteins that mediate the chronic inflammatory cascade, LFA-1 and ICAM-1. Phase I studies evaluated the compound in concentrations up to 5%, while Phase II studies evalu- ated the compound in 0.1%, 1.0%, and 5.0% concentrations. "It works on T-cells like topical cyclosporine 0.05% does, but in a different man- ner," Dr. de Luise said. "The two could be used synergistically." Glucocorticoids Overall, selective glucocorticoid receptor agonists are less likely to transactivate than steroids because they have lower glucocorticoid re- ceptor-DNA interactions.1 Mapracorat (Bausch + Lomb, Rochester, N.Y.): A novel glucocorti- coid receptor agonist that has been shown to inhibit cytokines IL-6, IL-8, and MCP-1 with "comparable efficacy and potency as dexametha- sone."1 EGP-437 (dexamethasone, EyeGate Pharma, Waltham, Mass.): Using the company's iontophoresis system, EyeGate is evaluating EGP-437 in a low dose (Ocular Iontophoresis with EGP-437 4.0 mA- min at 1.5 mA) and in high doses (Ocular Iontophoresis with EGP-437 6.5 mA-min at 2.5 mA) for the treat- ment of dry eye. EW References 1. Cavet ME, Harrington KL, Ward KW, Zhang J-Z. Mapracorat, a novel selective glucocorti- coid receptor agonist, inhibits hyperosmolar- EyeWorld factoid Nearly 5 million Americans 50 years of age and older are estimated to have dry eye Source: National Eye Institute, National Institutes of Health 1. DuoVisc® OVD Product Insert. © 2011 Novartis 11/11 VIS11628JAD Only One System Delivers the Shield of PROTECTION. DuoVisc® VISCOAT® Viscoelastic System offers both the endothelial protection of chondroitin sulfate in OVD with the proven mechanical protection and space maintenance found in PROVISC® OVD.1 One System. No Compromises. induced cytokine release and MAPK pathways in human corneal epithelial cells. Molecular Vis 2010;16:1791-800. Editors' note: Dr. de Luise has no financial interests related to this article. Dr. Lemp has financial interests with TearLab Corp. Contact information De Luise: 203-232-9028, vdeluisemd@gmail.com Lemp: 202-255-6842, malemp@lempdc.com